Stock Screener App

Frei -

Installieren

3.10

0.32% -0.010

Fate Therapeutics Inc (FATE)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Fate Therapeutics Inc Aktie (FATE) Neueste Nachrichten

Needham Maintains Fate Therapeutics(FATE.US) With Hold Rating, Announces Target Price $3.11 - Moomoo

Fate Therapeutics’ FT-839 gains IND clearance - BioWorld News

H.C. Wainwright reiterates Fate Therapeutics stock rating at buy By Investing.com - Investing.com Canada

Can Fate Therapeutics (NASDAQ:FATE) Boost Healthcare Stocks? - Kalkine Media

FT819 shows first clinical activity in systemic sclerosis - CRISPR Medicine News

Update: Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839 - Moomoo

FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials - Stocktwits

Sector Update: Healthcare - Moomoo

Fate Therapeutics Shares Rise After FDA Clears Investigational New Drug Application for FT839 - marketscreener.com

Fate Therapeutics gains after IND clearance (FATE:NASDAQ) - Seeking Alpha

Fate Therapeutics Receives FDA Clearance Of Investigational New Drug Application For FT839 Product Candidate - marketscreener.com

FDA clears Fate Therapeutics' FT839 for autoimmune trial push - Stock Titan

Fate Therapeutics (FATE) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $FATE - MarketBeat

Fate Therapeutics: There Is A Bull Case, But It's Going To Take Time To Develop (Rating Downgrade) - Seeking Alpha

Fate Therapeutics looks to its pipeline as investors weigh long-term prospects - ad-hoc-news.de

Fate Therapeutics Insiders Benefit From Selling Stock At US$1.54 - simplywall.st

Fate Therapeutics to present FT819 data at stem cell meeting - Investing.com

Fate Therapeutics Announces Preliminary FT819 Data in Systemic Sclerosis for ISSCR 2026 Presentation - Quiver Quantitative

Fate Therapeutics to present FT819 data at stem cell meeting By Investing.com - Investing.com Canada

Fate Therapeutics to show early FT819 data in systemic sclerosis - Stock Titan

Fate Therapeutics (FATE) Slides to $2.92 as Support Levels Come Into FocusVolume Gap - dars.gov.et

Fate Therapeutics focuses on cell-based immunotherapy and long-term growth prospects - ad-hoc-news.de

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences - The Manila Times

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs - Sahm

Fate Therapeutics(FATE) Stock Options Chain | Quotes & News - Moomoo

Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Index - marketscreener.com

Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 3000E Index - marketscreener.com

Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Value Benchmark - marketscreener.com

Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 2000 Dynamic Index - marketscreener.com

Fate Therapeutics, Inc.(NasdaqGM: FATE) dropped from Russell 3000E Value Benchmark - marketscreener.com

Fate Therapeutics Stock Pops As FT836 Cancer Data Impress Traders - StocksToTrade

Fate Therapeutics, Inc.(NasdaqGM:FATE) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com

Fate Therapeutics Inc (FATE) Stock Price, Quote, News & History - Benzinga

F6T Forecast — Price Target — Prediction for 2027 - TradingView

Fate Therapeutics sets out next steps, biotech stock in focus after cash preservation move - ad-hoc-news.de

Fate Therapeutics, Inc. Actuals & Estimates (DUS:F6T) - TradingView

Fate Therapeutics Inc (FATE) Valuation: PE, PB & Fair Value Analysis - TradingKey

Fate Therapeutics, Inc. Actuals & Estimates (TRADEGATE:F6T) - TradingView

Fate Therapeutics, Inc. Actuals & Estimates (NASDAQ:FATE) - TradingView

Enterprise value to revenue forward of Fate Therapeutics, Inc. – NASDAQ:FATE - TradingView

Fate Therapeutics, Inc. Actuals & Estimates (FWB:F6T) - TradingView

Price to earnings forward of Fate Therapeutics, Inc. – NASDAQ:FATE - TradingView

Price to book forward of Fate Therapeutics, Inc. – NASDAQ:FATE - TradingView

Enterprise value to EBITDA forward of Fate Therapeutics, Inc. – NASDAQ:FATE - TradingView

Price to sales forward of Fate Therapeutics, Inc. – NASDAQ:FATE - TradingView

FATE Forecast — Price Target — Prediction for 2027 - TradingView

H.C. Wainwright Reaffirms Their Buy Rating on Fate Therapeutics (FATE) - The Globe and Mail

Fate Therapeutics Inc (FATE) Institutional Confidence - TradingKey

H.C. Wainwright Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $7 - Moomoo

Fate Therapeutics’s FT819 Progress Keeps My Bull Case Alive (NASDAQ:FATE) - Seeking Alpha

Fate Therapeutics (FATE) Gets a Buy from Mizuho Securities - The Globe and Mail

Fate Therapeutics Inc (FATE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

TRDA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Fate Therapeutics Inc (FATE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Fate Therapeutics Inc (FATE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Fate Therapeutics Inc (FATE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Fate Therapeutics Inc (FATE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Fate Therapeutics Inc (FATE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Fate Therapeutics Inc (FATE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

FATE Stock Price, Quote & Chart - ChartMill

Fate Therapeutics Shareholders Back Directors and Governance Plans - The Globe and Mail

Redmile director nominee awarded 87,900 Fate Therapeutics (FATE) stock options - Stock Titan

Fate Therapeutics (FATE) director granted 87,900 stock options at $2.06 - Stock Titan

Director Yuan Xu receives 87,900 Fate Therapeutics (FATE) stock options at $2.06 - Stock Titan

FATE Therapeutics (NASDAQ: FATE) director awarded 87,900 stock options as equity pay - Stock Titan

Fate Therapeutics (FATE) director receives 87,900 stock options at $2.06 strike - Stock Titan

Fate Therapeutics (FATE) director receives 87,900 stock options award - Stock Titan

RPRX

$56.43

2.64%

INSM

$115.61

2.24%

ROIV

$35.97

2.28%

MRNA

$68.27

10.83%

ONC

$298.70

1.36%

RVMD

$186.88

2.22%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters